[A trial of the use of the new Russian preparation oxymetacil in patients with chronic nonspecific lung diseases].

The trial of oxymethacyl was conducted in 20 CNSPD patients. Clinicoimmunological examinations provided evidence on the drug effectiveness as it stimulated cell immunity, phagocytosis, was well tolerated, caused no side effects. The highest response was achieved in combination of oxymethacyl with antibacterial therapy. Normalization of clinical and immunological indices in CNPD patients suggests immunocorrective effect of oxymethacyl.